Researchers at M. D. Anderson Cancer Center identified an association between mucinous carcinoma and multiple undetected tumors, contrary to its long-considered favorable prognosis. The study suggests that these patients may need more treatment and additional screening.
A new hybrid agent, T-DM1, has shown promising results in a Phase 2 clinical trial for metastatic HER2-positive breast cancer. The compound shrunk tumors by 30% or more in 40% of women with confirmed HER2-positive cancers, and had a total clinical benefit rate of approximately 53%.
Using Herceptin with chemotherapy reduces the risk of cancer recurrence by 25% compared to using it after chemotherapy. This new standard of care may benefit up to 10,000 women worldwide each year.